GlassScriptPhysician profile
Lori A Lavelle
NPI 1639162241
$13,522.46
in general payments reported to CMS, 2019-2025
33 companies · $3,273 in 2025
The $3,273 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $1,058 · 2021: $1,374 · 2022: $1,413 · 2023: $2,238 · 2024: $2,723 · 2025: $3,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,234.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,138.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,805.41 | 2019-2025 | |
| Pfizer INC. | $1,585.57 | 2019-2025 | |
| Amgen INC. | $1,451.55 | 2019-2025 | Otezla, Krystexxa, Tavneos |
| Janssen Biotech, INC. | $1,043.66 | 2019-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $754.79 | 2021-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $503.58 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $486.51 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $292.79 | 2020-2025 | Orencia |
| Ucb, INC. | $285.36 | 2019-2024 | Cimzia, Bimzelx |
| Genzyme Corporation | $197.36 | 2020-2024 | |
| Aurinia Pharma U.S., INC. | $169.42 | 2021-2024 | Lupkynis |
| Novo Nordisk INC | $116.12 | 2022-2024 | Wegovy |
| Ani Pharmaceuticals, INC. | $97.90 | 2022-2023 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $71.82 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65.42 | 2021-2025 | Taltz |
| Sanofi-Aventis U.S. LLC | $65.00 | 2019 | |
| Bioventus LLC | $47.63 | 2025 | Durolane |
| Mallinckrodt Hospital Products INC. | $38.51 | 2021-2025 | Acthar |
| Pacira Pharmaceuticals Incorporated | $37.18 | 2023 | Iovera, Zilretta |
| Genentech USA, INC. | $30.55 | 2019 | |
| Kyowa Kirin, INC. | $29.89 | 2025 | |
| Pacira Therapeutics, INC. | $26.57 | 2020 | |
| Medexus Pharma, INC. | $21.96 | 2019 | |
| Invivyd INC | $21.79 | 2025 | Pemgarda |
| Sobi, INC | $21.18 | 2025 | |
| Fresenius Kabi USA, LLC | $21.15 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.90 | 2023 | Cyltezo |
| Swing Therapeutics, INC. | $18.64 | 2025 | Stanza |
| Eisai INC. | $17.44 | 2020 | |
| Hikma Pharmaceuticals USA | $16.70 | 2019 | |
| Sebela Pharmaceuticals INC. | $16.70 | 2019 | |
| Amniox Medical, INC. | $5.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Lavelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.